Results 111 to 120 of about 1,222 (132)
Vaccine, 2020 Naturally occurring smallpox has been eradicated but research stocks of variola virus (VARV), the causative agent of smallpox, still exist in secure laboratories. Clandestine stores of the virus or resurrection of VARV via synthetic biology are possible and have led to concerns that VARV could be used as a biological weapon.
Douglas W Grosenbach +2 more
exaly +3 more sources
International Immunopharmacology, 2023 Recently, there has been an uptick in reported cases of monkeypox (Mpox) in Africa and across the globe. This prompted us to investigate the efficacy of the two vaccines that can prevent Mpox, the modified vaccinia Ankara virus (MVA) vaccine and ACAM2000 vaccine.
Hany M Abd El-Lateef +2 more
exaly +3 more sources
Expert Review of Vaccines, 2009 Quarantine, case tracing and population vaccination facilitated the global eradication, in 1980, of variola virus, the causative agent of smallpox. The vaccines used during the eradication period, including Dryvax, the smallpox vaccine used in the USA, were live vaccinia and cowpoxvirus-based vaccines, which induced long-lasting and cross-protective ...
Scott Parker +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Prospective safety surveillance study of ACAM2000 smallpox vaccine in deploying military personnel
Vaccine, 2020To compare rates of myopericarditis, severe and serious dermatological or neurological events, and other adverse events in deploying US military personnel who received or did not receive ACAM2000® (Smallpox [Vaccinia] Vaccine, Live) vaccine and to evaluate potential risk factors for development of myopericarditis.Prospective observational cohort study ...
Dennis Faix +2 more
exaly +3 more sources
Enhanced safety surveillance study of ACAM2000 smallpox vaccine among US military service members
Vaccine, 2021To evaluate the rates of myopericarditis (primary objective) and rates of cardiovascular and neurological adverse events (secondary objectives) in temporal association with ACAM2000® smallpox vaccine.Observational cohort study conducted through monthly surveillance from 2009 to 2017 of electronic medical records of military service members (SM) for pre-
Michael Decker +2 more
exaly +3 more sources
ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine
Expert Opinion on Investigational Drugs, 2008Due to concern over i) expiration of currently available calf-lymph vaccine (Dryvax); ii) calf lymph as a vaccine (bovine spongiform encephalopathy [BSE], other possible contaminations and animal welfare); and iii) use of variola as a weapon for bioterrorism, a new and safer vaccinia-based smallpox vaccine derived from new cell culture-based technology
Jeffrey S Kennedy
exaly +3 more sources
Vaccine, 2009
Currently, more than half of the world's population has no immunity against smallpox variola major virus. This phase I double-blind, randomized trial was conducted to compare the safety and immunogenicity of two clonally derived, cell-culture manufactured vaccinia strains, ACAM1000 and ACAM2000, to the parent vaccine, Dryvax.
Getahun Abate +2 more
exaly +3 more sources
Currently, more than half of the world's population has no immunity against smallpox variola major virus. This phase I double-blind, randomized trial was conducted to compare the safety and immunogenicity of two clonally derived, cell-culture manufactured vaccinia strains, ACAM1000 and ACAM2000, to the parent vaccine, Dryvax.
Getahun Abate +2 more
exaly +3 more sources
Journal of Virology, 2022 Continuous emergence of SARS-CoV-2 variants which cause breakthrough infection from the immunity induced by current spike protein-based COVID-19 vaccines highlights the need for new generations of vaccines that will induce long-lasting immunity against a wide range of the variants. To this end, we investigated the protective efficacy of the recombinant
Stephanie A Booth +2 more
exaly +3 more sources
Assessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques. [PDF]
Journal of Virology, 2013 ABSTRACT To support the licensure of a new and safer vaccine to protect people against smallpox, a monkeypox model of infection in cynomolgus macaques, which simulates smallpox in humans, was used to evaluate two vaccines, Acam2000 and Imvamune, for protection against disease.
Simon Funnell +2 more
exaly +3 more sources